Susanne Schaffert Susanne Schaffert was appointed Chairperson and President of Advanced Accelerator Applications (AAA) in January 2018, following the completion of a tender offer for the company by Novartis. Prior to this, Susanne was the Head of Region Europe at Novartis Oncology, where she was responsible for leading Novartis’ Oncology Business Unit in the European Region, marketing key products in lung, breast and renal cancer as well as hematology and coordinating the entire Oncology operations for EU countries. Susanne is a member of the Novartis Oncology Executive Committee and R&D Portfolio management board, as well as a member of the Board of Novartis AG Germany and the GSK JV OTC Board. From 2010 to 2012, Susanne served as the Head of Investor Relations for Novartis Group, reporting to the Chief Financial Officer. Before this, she served as Novartis Global Franchise Head for Immunology and Infectious Diseases. Susanne first joined Novartis Germany in 1995, as a sales representative, and she has held a series of positions in Sales & Marketing with increasing responsibilities in both National and Global functions. Her roles have included Global Brand Director, Basel; Head of Marketing Oncology, Germany; Business Unit Head Oncology, Germany and Head of Northern & Central Europe for Novartis Oncology, managing a $1 billion business with more than 500 associates. Susanne holds a Ph.D. with honors in Organic Chemistry from University of Erlangen (Germany).
Niva Almaula is Director of Business Development for Advanced Accelerator Applications (AAA), a Novartis company. Prior to joining AAA in 2015, Niva was Managing Partner at Octane BioVentures, a strategic partnering services company for early stage life science ventures that she founded in 2013. Before this, Niva was Associate Director of Alliance Management at Dr Reddy’s Labs. From 2008 to 2010, she was Associate Director, Pipeline Sourcing, at Nycomed, which was later acquired by Takeda Pharmaceuiticals. Niva’s business development experience includes working in healthcare investment banking at BIO IB, and in academic technology transfer at Rockefeller University. She began her career as an equity research analyst at Mehta Partners, where she covered biotechnology companies spanning various therapeutic areas. Niva holds a Ph.D. in Biochemistry and Molecular Biology from Rutgers University in New Jersey.
Thierry Battle is Director of Quality Assurance for Advanced Accelerator Applications (AAA), a Novartis company. From 2013 to 2018, he was Corporate Quality Assurance Manager and then Senior Manager, during which time he enhanced the structure of quality systems for production sites and general corporate systems throughout the company. Prior to joining AAA, Thierry spent 12 years at Merck Serono, a biopharmaceutical company, where he advanced from Senior Scientist to Associate Director, and finally to Operations Manager and Quality Coordinator. Thierry is co-inventor of a patent, “microcapsules embedding recombinant transiently-transfected cells as an escape to the immune response,” issued in 2004. He has published over 20 peer review articles and has spoken at several conferences. Thierry holds a Doctor of Pharmacy degree from the University of Nancy I, a Master of Sciences in cardiovascular pharmacology from the University of Lyon I, and has a Ph.D. in cellular biology from the University Pierre et Marie Curie, Paris (joint contract INSERM U367 & Ciba-Geigy).
Philippe Dasse is Head of Technical Operations for Advanced Accelerator Applications (AAA), a Novartis company. From 2015 until August 2018, he also held the position of General Manager of AAA France. Philippe joined AAA shortly after the company was founded in 2002, as Responsible Qualified Person. One of his first mandates was to establish pharmaceutical production. Over the past 16 years, he has held multiple roles of increasing responsibility across various functions, including production, regulatory affairs, pharmacovigilance, and quality assurance. Prior to AAA, Philippe worked at Tours Hospital for three years as Hospital Pharmacist and one year in an industrial pharmaceutical company as Quality Assurance Manager. Philippe holds a Doctor of Pharmacy degree from University of Reims, an academic diploma in Radiopharmacy and Quality Assurance from University of Pharmacy Tours, and a Master’s of Science in bio-kinetics of markers from the University of Pharmacy Paris V.
Germo Gericke was appointed Head of Research and Development of Advanced Accelerator Applications (AAA), following the completion of a tender offer for the company by Novartis. Germo continues his role as a member of the Oncology Development Leadership Team at Novartis. Prior to joining AAA, Germo served as Franchise Global Program Head in the Oncology Global Development Unit of Novartis, where he leads cross-functional developent activities for compounds in full developent and life cycle management, including Sandostatin, Glivec, Afinitor, Exjade/Jadenu, Tykerb, Arzerra, osilodrostat and Signifor. Prior to moving to Oncology Global Drug Development in 2008, Germo served in strategic, commercial and general management roles with increasing responsibility across a range of therapeutic and geographic areas, including Global Therapeutic Area Head, Project Management at Novartis in 2007 and Business Unit Head Transplantation, Nordic Region at Novartis from 2005 to 2006. Germo joined Novartis in 2001 from McKinsey & Company where he was a member of the Global Healthcare Practice. Germo was a PostDoctoral Fellow at Dartmouth Medical School and holds a Medical Doctorate from the University of Heidelberg. He studied medicine at Charité University Hospital, Berlin.
Rachel Levine is global Director of Communications for Advanced Accelerator Applications (AAA), a Novartis company. Prior to joining AAA in 2016, Rachel spent eight years at Cleveland BioLabs, Inc., a publicly traded biotechnology company, as Director of Corporate Development and Communications and then as Vice President of Investor Relations. During her tenure, she led financing activities, investor and media relations, and internal communications, and supported business development and government relations activites. Rachel has specialized in the healthcare sector (including biotechnology, specialty pharmaceuticals, managed care, healthcare services, and medical device and delivery) since 2000. From 2005 to 2007, Rachel served as Managing Director for Grayling, a global integrated communications firm and division of Huntsworth PLC. Before this, she was Managing Director at The Anne McBride Company, a global investor and public relations advisory. Rachel holds a Bachelor’s of Business Administration, with honors from the University of Massachusetts (Amherst, MA).
Barak Palatchi was appointed Chief Commercial Officer of Advanced Accelerator Applications (AAA) in January 2018, following the completion of a tender offer for the company by Novartis. Barak was Oncology General Manager, UK & Ireland for Novartis from 2016 to February 2018, and a member of the Novartis Oncology Leadership Team, Region Europe. Prior to this, Barak was Oncology General Manager Israel for Novartis from 2012 to June 2016. Before this, he was Head of Marketing for Samsung Israel from 2011 to 2012. Prior to joining Samsung, Barak spent seven years with Pfizer Israel in roles of increasing responsibility including Public Affairs Director, Marketing Director and then Business Unit Director. Barak started his career in the U.S. working as a legislative assistant for New York Congressman Eliot Engel. Barak was a scholar at the Institute for Advance Strategic and Political Studies in Washington D.C., and holds a Bachelor of Arts in Political Science from Bar-Ilan University, Israel.
Thomas Travis was appointed Head of Strategy and Operational Planning of Advanced Accelerator Applications (AAA), following the completion of a tender offer for the company by Novartis. Prior to joining AAA, Thomas worked as part of Novartis Oncology’s Global Strategy team, where he focused on commercial excellence. Thomas joined Novartis from McKinsey & Company, where he was a member of the Pharmaceuticals and Medical Products Practice from 2013 to 2017. Thomas started his career as a chemical process engineer at Fluor Corporation, an engineering and construction company, before returning to school to study business. Thomas holds a Master of Business Administration, a Master of Engineering Management, and a Bachelor of Chemical Engineering from Northwestern University.